Laura Daley | Senior Director, Molecular & Cellular Biology
Catalent Pharma Solutions
Dr. Laura Daley is a Senior Director at Catalent Pharma Solution where she supports Cell Line Development, R&D, and Cell & Molecular Biology activities. Laura received her Ph.D. in Pharmacology and Physiology from the Saint Louis University School of Medicine before joining the Department of Pediatrics at Stanford University School of Medicine as a postdoctoral fellow. Her background includes the fields of stem cell biology, gene regulation, and genetic engineering. She has over 17 years of industry experience where she has played a fundamental role in immune cell gene editing developing applications to advance the Immuno-Oncology field. At Catalent, she continues to leverage her expertise in science, strategy, and innovation to advance products and technology contributing to the manufacturing of biologics.
Appearances:
Festival of Biologics Day 1 @ 17:30
Designing for Complexity: Workflow Solutions for Multifunctional Biologics
The biopharmaceutical industry is shifting from traditional monoclonal antibodies to multi-specific and structurally complex biologics to address increasingly personalized diseases. These formats pose challenges in expression, stability, and manufacturability, requiring advanced development platforms.
To address these demands, we’ve developed an integrated strategy using a proprietary CHO cell line engineered with over 100 dock sites across the genome. This design allows us to precisely control expression through copy number with universal vectors, enabling rapid screening of expression profiles and the generation of high-titer pools under 30 days. Complementing this is a high-throughput process development workflow that can be rapidly tailored to the unique requirements of complex molecules. This platform facilitates efficient optimization of both upstream and downstream parameters, ensuring stable, high-yield expression across a wide range of protein formats.
Together, these technologies provide a robust and scalable foundation for the development of next-generation biologics, delivering improved product quality and accelerated timelines. This integrated approach enables the reliable advancement of complex therapeutic candidates from early development through to clinical and commercial readiness.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events